statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT...

American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond

American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond PR...

Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m. ET...

Director At Exelixis Sells $576K Of Stock

Exelixis Announces Settlement of CABOMETYX (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement...

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the companys management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2024 Health...

The Analyst Verdict: Exelixis In The Eyes Of 5 Experts

Latest Ratings for EXEL
 DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Nov 2021RBC CapitalMaintainsOutperform Nov 2021HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings...

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and...

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT...

What Analysts Are Saying About Exelixis Stock

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Volume	1.69M
52-Wk High	$24.34
52-Wk Low	$18.64

EXEL Exelixis Inc

About

Feed

News

Sentiment

Earnings

Fundamentals